Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'PULSED DENDRITIC CELLS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 140 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Huarte, E; Sarobe, P; Lasarte, JJ; Brem, G; Weiss, EH; Prieto, J; Borras-Cuesta, F
      Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen

      INTERNATIONAL JOURNAL OF CANCER
    2. Zeh, HJ; Stavely-O'Carroll, K; Choti, MA
      Vaccines for colorectal cancer

      TRENDS IN MOLECULAR MEDICINE
    3. Nawrocki, S; Wysocki, PJ; Mackiewicz, A
      Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer

      EXPERT OPINION ON BIOLOGICAL THERAPY
    4. Wang, E; Phan, GQ; Marincola, FM
      T-cell-directed cancer vaccines: the melanoma model

      EXPERT OPINION ON BIOLOGICAL THERAPY
    5. Fishman, M; Seigne, J; Antonia, S
      Novel therapies for renal cell carcinoma

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    6. Matzku, S; Zoller, M
      Specific immunotherapy of cancer in elderly patients

      DRUGS & AGING
    7. Fagnoni, FF; Della Cuna, GR
      Immunotherapy: On the edge between experimental and clinical oncology

      JOURNAL OF CHEMOTHERAPY
    8. Poloso, N; Nagarajan, S; Bumgarner, GW; Zampell, JC; Selvaraj, P
      Designer cancer vaccines made easy: Protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines

      FRONTIERS IN BIOSCIENCE
    9. Gerard, CM; Baudson, N; Kraemer, K; Ledent, C; Pardoll, D; Bruck, C
      Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice

      CLINICAL CANCER RESEARCH
    10. Maecker, HT; Auffermann-Gretzinger, S; Nomura, LE; Liso, A; Czerwinski, DK; Levy, R
      Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry

      CLINICAL CANCER RESEARCH
    11. Sicard, H; Al Saati, T; Delsol, G; Fournie, JJ
      Synthetic phosphoantigens enhance human V gamma 9V delta 2 T lymphocytes killing of non-Hodgkin's B lymphoma

      MOLECULAR MEDICINE
    12. Liso, A; Benedetti, R; Flenghi, L; Falini, B
      Vaccine therapy of B cell malignancies: Different strategies for a novel approach

      LEUKEMIA & LYMPHOMA
    13. Agrawal, SG; Marquet, J; Plumas, J; Rouard, H; Delfau-Larue, MH; Gaulard, P; Boumsell, L; Reyes, F; Bensussan, A; Farcet, JP
      Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue

      INTERNATIONAL IMMUNOLOGY
    14. Renner, C; Kubuschok, B; Trumper, L; Pfreundschuh, M
      Clinical approaches to vaccination in oncology

      ANNALS OF HEMATOLOGY
    15. Weth, R; Christ, O; Stevanovic, S; Zoller, M
      Gene delivery by attenuated Salmonella typhimurium: Comparing the efficacyof helper versus cytotoxic T cell priming in tumor vaccination

      CANCER GENE THERAPY
    16. Rousseau, RF; Hirschmann-Jax, C; Takahashi, S; Brenner, MK
      Cancer vaccines

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    17. Renkvist, N; Castelli, C; Robbins, PF; Parmiani, G
      A listing of human tumor antigens recognized by T cells

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    18. Westermann, J; Reich, G; Kopp, J; Haus, U; Dorken, D; Pezzutto, A
      Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    19. Streeter, PR; Minster, NI; Kahn, LE; Hood, WF; Vickery, LE; Thurman, TL; Monahan, JB; Welply, JK; McKearn, JP; Woulfe, SL
      Progenipoietins: Biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor

      EXPERIMENTAL HEMATOLOGY
    20. Siemens, DR; Ratliff, TL
      Vaccines in urologic malignancies

      UROLOGICAL RESEARCH
    21. Moingeon, P
      Cancer vaccines

      VACCINE
    22. Robert, C
      Immunotherapy for melanoma: how can tolerance be overcome?

      ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
    23. Gravekamp, C
      Tailoring cancer vaccines to the elderly: the importance of suitable mousemodels

      MECHANISMS OF AGEING AND DEVELOPMENT
    24. Schultze, JL; Maecker, B; von Bergwelt-Baildon, MS; Anderson, KS; Vongerheide, RH
      Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens

      VOX SANGUINIS
    25. Glaser, A; Schuler-Thurner, B; Feuerstein, B; Zingsem, J; Zimmermann, R; Weisbach, V; Eckstein, R
      Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma

      TRANSFUSION
    26. Malmberg, KJ; Arulampalam, V; Ichihara, F; Petersson, M; Seki, K; Andersson, T; Lenkei, R; Masucci, G; Pettersson, S; Kiessling, R
      Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappa B activation

      JOURNAL OF IMMUNOLOGY
    27. Keogh, E; Fikes, J; Southwood, S; Celis, E; Chesnut, R; Sette, A
      Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

      JOURNAL OF IMMUNOLOGY
    28. Zoller, M; Christ, O
      Prophylactic tumor vaccination: Comparison of effector mechanisms initiated by protein versus DNA vaccination

      JOURNAL OF IMMUNOLOGY
    29. Tangri, S; Ishioka, GY; Huang, XQ; Sidney, J; Southwood, S; Fikes, S; Sette, A
      Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide

      JOURNAL OF EXPERIMENTAL MEDICINE
    30. Kessler, JH; Beekman, NJ; Bres-Vloemans, SA; Verdijk, P; van Veelen, PA; Kloosterman-Joosten, AM; Vissers, DCJ; ten Bosch, GJA; Kester, MGD; Sijts, A; Drijfhout, JW; Ossendorp, F; Offringa, R; Melief, CJM
      Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis

      JOURNAL OF EXPERIMENTAL MEDICINE
    31. Veelken, H
      Tumor vaccination via the use of monoclonal antibodies

      INTERNIST
    32. Gjertsen, MK; Buanes, T; Rosseland, AR; Bakka, A; Gladhaug, I; Soreide, O; Eriksen, JA; Moller, M; Baksaas, I; Lothe, RA; Saeterdal, I; Gaudernack, G
      Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma

      INTERNATIONAL JOURNAL OF CANCER
    33. Benlalam, H; Labarriere, N; Linard, B; Derre, L; Diez, E; Pandolfino, MC; Bonneville, M; Jotereau, F
      Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy

      EUROPEAN JOURNAL OF IMMUNOLOGY
    34. Kobayashi, H; Lu, J; Celis, E
      Identification of helper T-cell epitopes that encompass or lie proximal tocytotoxic T-cell epitopes in the gp100 melanoma tumor antigen

      CANCER RESEARCH
    35. Brossart, P; Schneider, A; Dill, P; Schammann, T; Grunebach, F; Wirths, S; Kanz, L; Buhring, HJ; Brugger, W
      The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-Lymphocytes

      CANCER RESEARCH
    36. Trojan, A; Witzens, M; Schultze, JL; Vonderheide, RH; Harig, S; Krackhardt, AM; Stahel, RA; Gribben, JG
      Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule

      CANCER RESEARCH
    37. Ravaud, A
      Cell therapy for solid tumors

      BULLETIN DU CANCER
    38. Armstrong, A; Dermime, S
      Developing effective cancer vaccines: design and monitoring are critical

      BRITISH JOURNAL OF CANCER
    39. Tanaka, H; Tsunoda, T; Nukaya, I; Sette, A; Matsuda, K; Umano, Y; Yamaue, H; Takesako, K; Tanimura, H
      Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas

      BRITISH JOURNAL OF CANCER
    40. McAfee, JG
      The impact of recent advances in immunology and cancer therapy on nuclear medicine

      SEMINARS IN NUCLEAR MEDICINE
    41. Tjoa, BA; Murphy, GP
      Progress in active specific immunotherapy of prostate cancer

      SEMINARS IN SURGICAL ONCOLOGY
    42. Carmon, L; Tzehoval, E; Tirosh, B; el-Shami, KM; Bar-Haim, E; Vadai, E; Feldman, M; Eisenbach, L
      Anti-tumor vaccination in heterozygous congenic F1 mice: Presentation of tumor-associated antigen by the two parental class I alleles

      JOURNAL OF IMMUNOTHERAPY
    43. Ressing, ME; van Driel, WJ; Brandt, RMP; Kenter, GG; de Jong, JH; Bauknecht, T; Fleuren, GJ; Hoogerhout, P; Offringa, R; Sette, A; Celis, E; Grey, H; Trimbos, BJ; Kast, WM; Melief, CJM
      Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma

      JOURNAL OF IMMUNOTHERAPY
    44. Swiniarski, H; Wolf, SF; Sturmhoefel, K; Peterson, RL; Dorner, AJ; O'Toole, M
      IL-12-dependent enhancement of CTL response to weak class I-restricted peptide immunogens requires coimmunization with T helper cell immunogens

      CLINICAL IMMUNOLOGY
    45. Strong, TV
      Gene therapy for carcinoma of the breast - Genetic immunotherapy

      BREAST CANCER RESEARCH
    46. Pietersz, GA; Apostolopoulos, V; McKenzie, IFC
      Generation of cellular immune responses to antigenic tumor peptides

      CELLULAR AND MOLECULAR LIFE SCIENCES
    47. Tjoa, BA; Salgaller, ML
      Progress in active-specific immunotherapy of brain malignancies

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    48. Karanikas, V; Lodding, J; Maino, VC; McKenzie, IFC
      Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy

      CLINICAL CANCER RESEARCH
    49. Batra, RK; Sharma, S; Dubinett, SM
      New gene and cell-based therapies for lung cancer

      SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
    50. Dubinett, SM; Batra, RK; Miller, PW; Sharma, S
      Tumor antigens in thoracic malignancy

      AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
    51. Chaperot, L; Jacob, MC; Molens, JP; Manches, O; Bensa, JC; Plumas, J
      From the study of tumor cell immunogenicity to the generation of antitumorcytotoxic cells in non-Hodgkin's lymphomas

      LEUKEMIA & LYMPHOMA
    52. Brinckerhoff, LH; Thompson, LW; Slingluff, GL
      Melanoma vaccines

      CURRENT OPINION IN ONCOLOGY
    53. Sinkovics, JG; Horvath, JC
      Vaccination against human cancers

      INTERNATIONAL JOURNAL OF ONCOLOGY
    54. Kim, TS; Chung, SW; Kim, SH; Kang, BY; Hwang, SY; Lee, JW
      Genetically engineered fibroblasts with antigen-presenting capability: Efficient induction of an antigen-specific cytotoxic T-lymphocyte response andprotection against tumor development in vivo

      CANCER GENE THERAPY
    55. Nabeta, Y; Sahara, H; Suzuki, K; Kondo, H; Nagata, M; Hirohashi, Y; Sato, Y; Wada, Y; Sato, T; Wada, T; Yamashita, T; Kikuchi, K; Sato, N
      Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma

      JAPANESE JOURNAL OF CANCER RESEARCH
    56. Bendandi, M
      Anti-idiotype vaccines for human follicular lymphoma

      LEUKEMIA
    57. Dietrich, PY; Walker, PR
      Tumour tolerance and immune scape to apoptosis

      M S-MEDECINE SCIENCES
    58. Bremers, AJA; Kuppen, PJK; Parmiani, G
      Tumour immunotherapy: the adjuvant treatment of the 21st century?

      EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    59. Meidenbauer, N; Harris, DT; Spitler, LE; Whiteside, TL
      Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

      PROSTATE
    60. Avigan, D; Wu, Z; Joyce, R; Elias, A; Richardson, P; McDermott, D; Levine, J; Kennedy, L; Giallombardo, N; Hurley, D; Gong, J; Kufe, D
      Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer

      BONE MARROW TRANSPLANTATION
    61. Apostolopoulos, V; Barnes, N; Pietersz, GA; McKenzie, IFC
      Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses

      VACCINE
    62. Kim, TS; Chung, SW; Hwang, SY
      Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7

      VACCINE
    63. Bartholeyns, J; Bardot, V; Chokri, M; Romet-Lemonne, JL
      Adoptive immunotherapy: present status and perspectives in cancer treatment.

      REVUE DE MEDECINE INTERNE
    64. Shlyakhovenko, VA
      Modern trends in cancer vaccinotherapy

      EXPERIMENTAL ONCOLOGY
    65. Curiel-Lewandrowski, C; Demierre, MF
      Advances in specific immunotherapy of malignant melanoma

      JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
    66. Kim, CH; Todoroki, T; Matsumura, M; Ohno, T
      Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    67. Tsuge, T; Yamakawa, M; Tsukamoto, M
      Infiltrating dendritic/Langerhans cells in primary breast cancer

      BREAST CANCER RESEARCH AND TREATMENT
    68. Tartour, E; Fridman, WH
      Cancer vaccines 2000

      IMMUNOLOGY LETTERS
    69. Kerr, DJ; Midgley, RS
      Immunotherapy for colorectal cancer: Potential application in an adjuvant setting

      SEMINARS IN ONCOLOGY
    70. Hoffman, DMJ; Gitlitz, BJ; Belldegrun, A; Figlin, RA
      Adoptive cellular therapy

      SEMINARS IN ONCOLOGY
    71. Melief, CJM; Toes, REM; Medema, JP; Van der Burg, SH; Ossendorp, F; Offringa, R
      Strategies for immunotherapy of cancer

      ADVANCES IN IMMUNOLOGY, VOL 75
    72. Braathen, LR; Hunger, RE; Brand, CU
      Immunotherapy of malignant melanoma

      ZENTRALBLATT FUR CHIRURGIE
    73. Seo, N; Tokura, Y; Nishijima, T; Hashizume, H; Furukawa, F; Takigawa, M
      Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    74. Zoller, M; Matzku, S
      Vaccination: A future modality of cancer therapy

      DRUGS OF TODAY
    75. Gambotto, A; Cicinnati, V; Robbins, PD
      Genetic approaches for biologic therapy of cancer

      DRUGS OF TODAY
    76. Cochlovius, B; Stassar, M; Christ, O; Raddrizzani, L; Hammer, J; Mytilineos, I; Zoller, M
      In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program

      JOURNAL OF IMMUNOLOGY
    77. Warren, TL; Bhatia, SK; Acosta, AM; Dahle, CE; Ratliff, TL; Krieg, AM; Weiner, GJ
      APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC classI-restricted T cells

      JOURNAL OF IMMUNOLOGY
    78. Davila, E; Celis, E
      Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity

      JOURNAL OF IMMUNOLOGY
    79. Baxevanis, CN; Voutsas, IF; Tsitsilonis, OE; Gritzapis, AD; Sotiriadou, R; Papamichail, M
      Tumor-specific CD4(+) T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor

      JOURNAL OF IMMUNOLOGY
    80. Sun, YS; Song, MX; Stevanovic, S; Jankowiak, C; Paschen, A; Rammensee, HG; Schadendorf, D
      Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen

      INTERNATIONAL JOURNAL OF CANCER
    81. Noppen, C; Levy, F; Burri, L; Zajac, P; Remmel, E; Schaefer, C; Luscher, U; Heberer, M; Spagnoli, GC
      Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2

      INTERNATIONAL JOURNAL OF CANCER
    82. Roth, MD; Gitlitz, BJ; Kiertscher, SM; Park, AN; Mendenhall, M; Moldawer, N; Figlin, RA
      Granulocyte macrophage colony-stimulating factor and interleukin 4 enhancethe number and antigen-presenting activity of circulating CD14(+) and CD83(+) cells in cancer patients

      CANCER RESEARCH
    83. Gautier, F; Irminger-Finger, I; Gregoire, M; Meflah, K; Harb, J
      Identification of an apoptotic cleavage product of BARD1 as an autoantigen: A potential factor in the antitumoral response mediated by apoptotic bodies

      CANCER RESEARCH
    84. Lu, J; Celis, E
      Use of two predictive algorithms of the World Wide Web for the identification of tumor-reactive T-cell epitopes

      CANCER RESEARCH
    85. Kobayashi, H; Wood, M; Song, YS; Appella, E; Celis, E
      Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen

      CANCER RESEARCH
    86. Santin, AD
      Lymph node metastases - The importance of the microenvironment

      CANCER
    87. Liu, YJ; Blom, B
      Introduction: TH2-inducing DC2 for immunotherapy

      BLOOD
    88. Pinilla-Ibarz, J; Cathcart, K; Korontsvit, T; Soignet, S; Bocchia, M; Caggiano, J; Lai, L; Jimenez, J; Kolitz, J; Scheinberg, DA
      Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

      BLOOD
    89. Fleischhauer, K; Gattinoni, L; Lietti, G; Zino, E; Bordignon, C; Traversari, C
      Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules

      TISSUE ANTIGENS
    90. Horig, H; Kaufman, HL
      Current issues in cancer vaccine development

      CLINICAL IMMUNOLOGY
    91. Schirmbeck, R; Reimann, J
      Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells

      BIOLOGICAL CHEMISTRY
    92. Bilbao, G; Contreras, JL; Curiel, DT
      Advances in cancer gene therapy

      EXPERT OPINION ON THERAPEUTIC PATENTS
    93. Kammula, US; Marincola, FM
      Cancer immunotherapy: Is there real progress at last?

      BIODRUGS
    94. O'Donnell, DM; Patel, PM; Sousa, CRE
      Gene manipulation in the induction of anti-tumor immunity

      GENE THERAPY
    95. de Cerio, ALD; Casares, N; Lasarte, JJ; Sarobe, P; Perez-Mediavilla, LA; Ruiz, M; Prieto, J; Borras-Cuesta, F
      T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides

      INTERNATIONAL IMMUNOLOGY
    96. Sun, YS; Paschen, A; Schadendorf, D
      Cells-based vaccination against melanoma - background, preliminary results, and perspective

      JOURNAL OF MOLECULAR MEDICINE-JMM
    97. Carbone, DP
      Molecular modalities in the treatment of lung cancer

      ONCOLOGY-NEW YORK
    98. Levy, Y
      Antigen presentation: physiology and perversion

      M S-MEDECINE SCIENCES
    99. Zitvogel, L; Faure, F
      Cancer immunotherapy

      M S-MEDECINE SCIENCES
    100. Bagot, M; Boumsell, L; Bensussan, A
      Contribution of immunotherapy for the treatment of T-cell lymphomas of theskin

      PRESSE MEDICALE


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 00:17:57